New cancer drug enters human testing for Tough-to-Treat cancers
Disease control
Completed
This early-stage study tested a new drug called PTX-100 in 25 patients with advanced cancers that had stopped responding to standard treatments. The main goals were to check the drug's safety, how the body processes it, and its initial effects on cancer-related proteins. Patients…
Phase: PHASE1 • Sponsor: Prescient Therapeutics, Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC